

CROI 2009 Poster Sessions

Monday, February 9	
7 am-7 pm	<i>Poster Hall open 7 am to 7 pm; all posters will be available for viewing for the duration of the conference</i>
1-2:30 pm	Poster Sessions
	<p>50. Viral Replication Cycle (posters 200-211)</p> <p>51. Viral Tropism, Entry, and Transmission (posters 212-219)</p> <p>52. Cellular Factors Affecting Viral Replication and Pathogenicity (posters 220-232)</p> <p>58. Molecular Characterization of Viral Epidemics (posters 280-291b)</p> <p>59. Molecular Epidemiology of HIV Transmission and Distribution (posters 292-295)</p> <p>60. Molecular Epidemiology: Zoonoses, Recombination, and Co-infection (posters 296-304)</p> <p>61. New Insights into T Cell Activation and Turnover (posters 305-309)</p> <p>62. Scientific Discoveries in CD4 T Cell Function (posters 310-317)</p> <p>63. TH17 and Treg: The Other CD4 T Cells (posters 318-323)</p> <p>64. What's New in Mucosal Immunity (posters 324-325)</p> <p>65. Improvements in Immune Assays (posters 326-328b)</p> <p>75. Viral and Host Factors in Immunopathogenesis (posters 388-397)</p> <p>76. Gut Pathogenesis and Mucosal Defenses (posters 398-405)</p> <p>84. Mechanisms of Neuropathogenesis (posters 446-457)</p> <p>97. Genome-wide Studies of HIV Control and Disease Progression (posters 541-547)</p> <p>98. Is Duffy Antigen Associated with Outcome of HIV Infection? (posters 548-549)</p> <p>99. Inhibitors of HIV Entry and Integration (posters 550-555)</p> <p>100. HIV RT, RNase H, Protease, and Maturation Inhibitors (posters 556-562)</p> <p>101. Novel HIV Inhibition Approaches: Vpu, RNAi, and Rapamycin (posters 563-565)</p> <p>102. Anti-HIV Activity of Acyclovir: Back to the Future (posters 566-567)</p> <p>103. New ARVs including Pharmacokinetics in Healthy Volunteers (posters 568-570)</p> <p>104. ART: Randomized Trials (posters 571a-581)</p> <p>110. Resistance to Integrase Inhibitors (posters 614-622)</p> <p>111. Biochemical Mechanisms of RTI Resistance (posters 623-629)</p> <p>112. Gag Mutations and Drug Resistance (posters 630-637)</p> <p>113. Resistance to Inhibitors of HIV-1 Entry (posters 638-641)</p> <p>124. Morbidity and Mortality: Non-AIDS Events (posters 706-711)</p> <p>125. Alterations in Blood Lipids and Body Fat (posters 712-720)</p> <p>132. Immune Responses to TB (posters 765-770)</p> <p>133. Immunologic Mechanisms and Clinical Features of IRIS (posters 771-775)</p> <p>139. Epidemiology of Hepatitis Co-infection (posters 798-806)</p> <p>140. Responses to HBV Vaccination (posters 807-809)</p> <p>141. HBV Virology and Outcomes (posters 810-812)</p> <p>142. HBV: Response to Therapy and Drug Resistance (posters 813a-817)</p> <p>152. Studies of Cancer Incidence (posters 859-860b)</p> <p>153. Viral Pathogenesis, Treatment, and Outcome of KSHV-associated Diseases (posters 861-864)</p> <p>154. HIV-associated Cervical and Anal Cancers (posters 865-867)</p> <p>155. Risk Factors, Prevalence, and Prognosis of HIV-associated Lymphomas (posters 868-872)</p> <p>156. Integrase Inhibitor Therapy in Children (posters 873-874)</p> <p>157. Response to ART in Children in Resource-constrained Settings (posters 875-878)</p> <p>158. Pharmacokinetics in Children (posters 879-887)</p> <p>159. Resistance after First-line Failure in Children (posters 888-891)</p> <p>171. ART Pharmacokinetics during Pregnancy and Infancy (posters 939-947)</p> <p>172. Complications of ART during Pregnancy and Delivery (posters 948-951)</p> <p>173. Outcomes of Prenatal NRTI Exposure (posters 952-953)</p> <p>183. Detecting Acute/Incident Infection (posters 988-995b)</p> <p>184. Rapid Tests for HIV Diagnosis (posters 996-997)</p> <p>189. Recent Discoveries in HIV Transmission (posters 1016-1023)</p> <p>190. Recent Discoveries in the Epidemiology of HIV Disease Progression (posters 1024-1027)</p>

CROI 2009 Poster Sessions

Tuesday, February 10	
7 am-7 pm	<i>Poster Hall open 7 am to 7 pm; all posters will be available for viewing for the duration of the conference</i>
1-2:30 pm	Poster Sessions
	<p>53. Host-cell Restriction Factors (posters 233-239)</p> <p>54. Viral Accessory Proteins and Cellular Restrictions (posters 240-261)</p> <p>66. New Insights into B Cells (posters 329-331)</p> <p>67. Recent Discoveries on Neutralizing Antibodies (posters 332-339)</p> <p>70. Insights into the Mechanisms of Elite Control (posters 356-361)</p> <p>71. Immune and Virologic Markers of HIV Elite Control (posters 362-367)</p> <p>77. Host and Viral Contributions to HIV Disease (posters 406-411)</p> <p>78. Compartments of HIV Infection (posters 412-415)</p> <p>79. HIV Latency and Reservoirs (posters 416-422)</p> <p>80. Latency, Reservoirs, and Impact of Treatment Intensification (posters 423a-428)</p> <p>85. Aging and Metabolic Syndromes as Risk Factors for Neurologic Disorders (posters 458-463)</p> <p>86. HCV and OIs in NeuroAIDS (posters 464-468b)</p> <p>87. Viral Infection of CNS Compartments (posters 469-473)</p> <p>89. Viral Genetics of HIV-1 Transmission (posters 487-492)</p> <p>90. Natural History of HIV Transmission (posters 493-501)</p> <p>93. Vaccines to Prevent Infection or Alter Disease Progression (posters 517-525)</p> <p>105. ART: Observational Studies (posters 582-586)</p> <p>106. Delivery of Care in Resource-constrained Settings (posters 587-593)</p> <p>117. Circulating Drug Resistance in HIV-infected Populations (posters 666-671)</p> <p>118. Transmission of Drug-resistant HIV (posters 672-678)</p> <p>119. Use of Novel Technologies to Understand HIV Drug Resistance (posters 679-685)</p> <p>120. Resistance Assays and Their Interpretation (posters 686-689)</p> <p>126. Subclinical Atherosclerosis and Cardiovascular Events: Role of HIV and ART (posters 721-731)</p> <p>127. Inflammatory Markers, ART, and Complications (posters 732-739)</p> <p>134. TB Diagnostics (posters 776-780)</p> <p>135. Drug Resistant TB: Diagnosis and Outcomes (posters 781-785)</p> <p>148. Immunologic Outcomes of HCV Co-infection (posters 836-838)</p> <p>149. Determinants of HCV Treatment Outcomes (posters 839-846)</p> <p>150. Influence of ART on HCV Co-infection (posters 847-854)</p> <p>151. HCV Virology and Impact of ART Interruption (posters 855-858)</p> <p>160. Viral and Host Factors Associated with Pediatric Disease (posters 892-894)</p> <p>161. Immune Response to HIV and Protective Vaccines in Children (posters 895-899b)</p> <p>162. Longitudinal Outcomes in Perinatally Infected Children (posters 900-901)</p> <p>163. Adolescent HIV Epidemic in Africa (posters 902-903)</p> <p>164. Screening and Barriers to Care for HIV-infected Adolescents (posters 904-906)</p> <p>168. Trends in MTCT in the US (posters 924-925)</p> <p>169. Risk Factors for MTCT (posters 926-930)</p> <p>170. Viral and Host Factors Associated with MTCT (posters 931-938)</p> <p>178. Genital HIV Shedding (posters 969-973)</p> <p>179. Cervical Disease (posters 974-975)</p> <p>180. Metabolic and Hormonal Abnormalities (posters 976-978)</p> <p>181. Effect of PMTCT Interventions on Maternal Outcomes (posters 979-985)</p> <p>182. ART Toxicity and Outcomes (posters 986-987b)</p> <p>185. Methods of Viral Load Monitoring (posters 998-1005)</p> <p>186. Use of Dried Blood for HIV Viral Load Monitoring (posters 1006-1009)</p> <p>194. STI Screening and Effect of ART (posters 1052-1053)</p> <p>195. HSV-2/HIV-1 Interactions (posters 1054-1056)</p> <p>196. Incident and Endemic Syphilis (posters 1057-1059)</p> <p>197. Acceptance and Influence of Male Circumcision (posters 1060-1064)</p> <p>198. Novel Microbicide Gels and Rings (posters 1065-1070)</p> <p>199. Prevention Strategies: Pre- and Post-exposure Prophylaxis (posters 1071-1079)</p>

CROI 2009 Poster Sessions

Wednesday, February 11	
7 am-6 pm	<i>Poster Hall open 7 am to 6 pm; all posters will be available for viewing for the duration of the conference</i>
1-2:30 pm	Poster Sessions
	<p>55. Regulation of Viral Latency (posters 262-267)</p> <p>56. Viral Reservoirs: Monocyte/Macrophage Studies (posters 268-274)</p> <p>57. Modulation of HIV by other Viruses (posters 275-279)</p> <p>68. The Expanding Role of Natural Killer Cells in HIV Infection (posters 340-346)</p> <p>69. New Discoveries in Antigen-presenting Cells and HIV (posters 347-355)</p> <p>72. Characterization of CD8 T Cell Function (posters 368-374)</p> <p>73. Mechanisms of CD8 T Cell Dysfunction (posters 375-381)</p> <p>74. TCR, MHC, and Viral Recognition or Escape (posters 382-387)</p> <p>81. Dynamics of HIV/SIV Infection (posters 429-433)</p> <p>82. Evolution of Tropism in HIV-infected Patients (posters 434-439b)</p> <p>83. HIV Evolution in vivo (posters 440-445)</p> <p>88. Clinical Studies and Therapy of CNS Infection (posters 474-486)</p> <p>91. Mucosal Infection (posters 502-507)</p> <p>92. Models for Prevention of HIV Transmission and Disease (posters 508-516)</p> <p>94. Novel Immune-based Therapies (posters 526-531)</p> <p>95. Immune Therapies Involving IL-2 (posters 532-536)</p> <p>96. New Therapeutic Vaccines and Strategies (posters 537-540)</p> <p>107. Outcomes on ART in Resource-constrained Settings: Randomized Trials and Observational Cohorts (posters 594-604)</p> <p>108. Second-line Therapy in Resource-constrained Settings (posters 605-610)</p> <p>109. Generic ARVs in Resource-constrained Settings (posters 611-613)</p> <p>114. Evolution of RT and PI Resistance in Patients (posters 642-650)</p> <p>115. Drug Resistance and Viral Fitness (posters 651-654)</p> <p>116. Outcomes of HIV Drug Resistance (posters 655-665)</p> <p>121. Pharmacokinetics and Pharmacogenetics of ARVs (posters 690-695)</p> <p>122. ARV Drug-Drug Interactions (posters 696-701)</p> <p>123. Sanctuary Sites and Intracellular Pharmacokinetics of ARVs (posters 702-705)</p> <p>128. Renal Dysfunction: Role of HIV and ART (posters 740-746)</p> <p>129. Non-viral Hepatic Complications: HIV and ART Effects (posters 747-751)</p> <p>130. Osteopenia and Osteoporosis (posters 752-761)</p> <p>131. Anemia and Lactic Acidosis (posters 762-764)</p> <p>136. TB Risk and Treatment Outcomes (posters 786-790)</p> <p>137. Cryptococcal Infection: Diagnosis and Treatment (posters 791-792)</p> <p>138. Viral OIs (posters 793-797)</p> <p>143. Hepatitis Delta Virus Co-infection (posters 818-819)</p> <p>144. Complications of Hepatitis Co-Infection (posters 820-823)</p> <p>145. Non-invasive Assessment of Liver Fibrosis (posters 824-829)</p> <p>146. Liver Fibrosis in Hepatitis Co-infection (posters 830-832)</p> <p>147. Outcomes of Liver Transplantation (posters 833-835)</p> <p>165. Prevention of TB and Treatment of HIV and TB in Children (posters 907-910)</p> <p>166. Complications, Toxicities, and Neurodevelopment in Children (posters 911-919)</p> <p>167. HIV-related Complications in Children in Resource-constrained Settings (posters 920-923)</p> <p>174. Resistance and Clinical Outcomes after Single Dose Nevirapine for PMTCT (posters 954-958b)</p> <p>175. Properties of Breast Milk and MTCT (posters 959-960)</p> <p>176. Infant Feeding and Infant Outcomes (posters 961-964)</p> <p>177. Diagnosing HIV Exposure in Infants (posters 965-968)</p> <p>187. Comparison of HIV Tropism Assays (posters 1010-1011)</p> <p>188. Novel Diagnostic Assays (posters 1012-1015)</p> <p>191. New Insights into Groups at Risk (posters 1028-1035)</p> <p>192. New Insights from Incidence and Prevalence Testing (posters 1036-1047)</p> <p>193. HIV Testing in Resource-constrained Settings (posters 1048-1051)</p>